In a phase II trial, Zhao et al. evaluated the combination of camrelizumab, an anti-PD-1, plus apatinib, an anti-VEGFR-2, as a neoadjuvant treatment for resectable NSCLC. Here, KDR is linked to non-small cell lung carcinoma.